GlassScriptPhysician profile
Anthony M Whitney
NPI 1700897394
$3,211.97
in general payments reported to CMS, 2019-2025
29 companies · $652 in 2025
The $652 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $313 · 2022: $703 · 2023: $741 · 2024: $803 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,113.55 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $364.19 | 2021-2025 | Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $214.59 | 2022-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $203.57 | 2021-2025 | Airsupra, Farxiga |
| Abbott Laboratories | $198.48 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $184.42 | 2021-2025 | |
| Abbvie INC. | $127.42 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $99.01 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $76.71 | 2023-2025 | Gvoke Hypopen |
| Medtronic, INC. | $75.16 | 2023-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim, Inceptiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.22 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $47.72 | 2025 | |
| Glaxosmithkline, LLC. | $45.88 | 2023 | Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $39.75 | 2022-2023 | |
| Esperion Therapeutics, INC. | $36.25 | 2024-2025 | Nexletol |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $35.85 | 2023 | Otezla, Repatha |
| Intra-Sana Laboratories | $35.11 | 2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Kowa Pharmaceuticals America, INC. | $33.68 | 2023 | Seglentis |
| Merck Sharp & Dohme LLC | $27.62 | 2021-2023 | Belsomra, Steglatro |
| Antares Pharma, INC. | $26.06 | 2025 | Xyosted |
| Inspire Medical Systems, INC. | $24.55 | 2025 | Inspire |
| Corcept Therapeutics | $24.16 | 2025 | Korlym |
| Nevro Corp. | $22.50 | 2023 | Senza |
| Phathom Pharmaceuticals, INC. | $19.22 | 2025 | Voquezna |
| Seqirus USA INC | $18.78 | 2022 | |
| Exact Sciences Corporation | $13.23 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $12.51 | 2021 | |
| Boston Scientific Corporation | $12.49 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Whitney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.